The hypothetical risk of illness is enough of a motivating factor for people to take action, according to a study published in the Journal of Health and Social Behavior.
The hypothetical risk of illness is enough of a motivating factor for people to take action, according to a study published in the Journal of Health and Social Behavior.
Co-authors Rene Almeling, assistant professor of sociology at Yale University, and Shana Kushner Gadarian, assistant professor of political science at Syracuse University, asked participants to imagine they faced a genetic risk for a disease and assessed who wanted to take what kind of actions in response.
“Medical sociologists contend that we are living in an era of surveillance medicine, in which the emphasis on risk blurs the lines between health and disease,” the authors contended.
Participants were randomly assigned a level of risk and a disease: heart disease, colon cancer, or Alzheimer’s disease. The authors found that as the level of risk increased from 20% to 80%, people were more likely to want to take action of all kinds, including seeking information about the disease, taking medications or undergoing surgery to manage the risk, and organizing finances.
“Social scientists have argued that we are now treating risk as if it were a disease, and these results provide strong evidence for that claim,” Dr Almeling said in a statement.
The researchers also asked the participants if they have a family member or close friend with their assigned disease, and were surprised to discover personal experience with the disease did not make a difference. According to the research, people responded to the hypothetical risk of disease by wanting to take action regardless of whether or not they have seen the disease up close.
“It is extremely important for social scientists and clinicians to understand how people respond to these risk numbers and how they are being used to make important life decisions,” Dr Almeling said. She added, “Studies like this can aid healthcare providers in offering genetic information with sufficient context to insure that people make the best decisions for themselves.”
According to the researchers, the across-the-board desire to take action in response to hypothetical risk information suggests that everyone is a “patient-in-waiting.”
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Understanding How Fitness Affects Digestive Diseases
April 18th 2025Exercise is a powerful modulator of gut health in patients with gastrointestinal (GI) conditions, as moderate activity can ease gut inflammation, reduce colorectal cancer risk, and relieve constipation, while intense workouts may backfire, causing reflux, GI bleeding, or gut barrier disruption.
Read More
FDA Greenlights Dupilumab for Chronic Spontaneous Urticaria, Marking First Approval in a Decade
April 18th 2025Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives and itching remain uncontrolled by antihistamines.
Read More